Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy

Liang, Zhaoyuan; Cui, Xinyue; Yang, Linqi; Hu, Qin; Li, Danyang; Zhang, Xiaofei; Han, Lu; Shi, Siwei; Shen, Yi; Zhao, Weijian; Ju, Qi; Deng, Xiongwei; Wu, Yan; Wang, Sheng

doi:10.1016/j.ijpharm.2021.121091

Cited by 17 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In preclinical studies, CpG ODNs have also recently been combined with the Adpgk neoantigen from the MC38 colorectal cancer ( 88 ). To form adjuvant/antigen nanocomplexes, the neoantigen was modified to contain 10 positively charged lysine residues, which allowed for the self-assembly of nanocomplexes between cationic peptide and anionic CpG.…”

Section: Combination Strategies To Improve Cancer Vaccinesmentioning

confidence: 99%

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Hernandez

Malek

2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer vaccines offer the potential to enhance T cell-mediated antitumor immunity by expanding and increasing the function of tumor-specific T cells and shaping the recall response against recurring tumors. While the use of cancer vaccines is not a new immunotherapeutic approach, the cancer vaccine field continues to evolve as new antigen types emerge and vaccine formulations and delivery strategies are developed. As monotherapies, cancer vaccines have not been very efficacious in part due to pre-existing peripheral- and tumor-mediated tolerance mechanisms that limit T cell function. Over the years, various agents including Toll-like receptor agonists, cytokines, and checkpoint inhibitors have been employed as vaccine adjuvants and immune modulators to increase antigen-mediated activation, expansion, memory formation, and T effector cell function. A renewed interest in this approach has emerged as better neoepitope discovery tools are being developed and our understanding of what constitutes an effective cancer vaccine is improved. In the coming years, cancer vaccines will likely be vital to enhance the response to current immunotherapies. In this review, we discuss the various types of therapeutic cancer vaccines, including types of antigens and approaches used to enhance cancer vaccine responses such as TLR agonists, recombinant interleukin-2 and interleukin-2 derivatives, and checkpoint inhibitors.

show abstract

Section: Combination Strategies To Improve Cancer Vaccinesmentioning

confidence: 99%

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Hernandez

Malek

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Besides, nanomaterials and hydrogels delivered neoantigen vaccines and adjuvants to lymph nodes and APCs in coordination. They promoted the maturation of APCs, and cross-presentation of antigens, and were retained in lymph nodes for a long time, playing a robust and durable anti-tumor effect [162][163][164]. Secondly, adjuvants were critical to successful cancer vaccines.…”

Section: How Can the Efficacy Of Neoantigen Vaccines Be Enhanced?mentioning

confidence: 99%

Engineering neoantigen vaccines to improve cancer personalized immunotherapy

Lv¹,

Dang²,

Liu³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Immunotherapy treatments harnessing the immune system herald a new era of personalized medicine, offering considerable benefits for cancer patients. Over the past years, tumor neoantigens emerged as a rising star in immunotherapy. Neoantigens are tumor-specific antigens arising from somatic mutations, which are proceeded and presented by the major histocompatibility complex on the cell surface. With the advancement of sequencing technology and bioinformatics engineering, the recognition of neoantigens has accelerated and is expected to be incorporated into the clinical routine. Currently, tumor vaccines against neoantigens mainly encompass peptides, DNA, RNA, and dendritic cells, which are extremely specific to individual patients. Due to the high immunogenicity of neoantigens, tumor vaccines could activate and expand antigen-specific CD4+ and CD8+ T cells to intensify anti-tumor immunity. Herein, we introduce the origin and prediction of neoantigens and compare the advantages and disadvantages of multiple types of neoantigen vaccines. Besides, we review the immunizations and the current clinical research status in neoantigen vaccines, and outline strategies for enhancing the efficacy of neoantigen vaccines. Finally, we present the challenges facing the application of neoantigens.

show abstract

“… 89 Besides, CpG ODNs with negatively charged hardly penetrate the cell membrane and are also easily degraded by nucleases in physiological conditions, 90 thus, CpG-ODNs were coated onto mesoporous silica NPs to facilitate the induction of cytokines by TLR9. 91 As a result of NPs protection, CpG/MSN-NH2 NPs showed enhanced serum stability, significant uptake by cells, and elevated cytokine levels. 90 , 92 In addition, the bisphosphonate (BP, alendronate)-stabilized calcium phosphate NPs (BCP NPs) were designed and developed to allow the encapsulation of plasmid DNA and surface coating of bovine serum albumin (BSA), and these stable and well-dispersed BCP NPs demonstrated excellent uptake efficiency, endo-lysosome escape property, and macrophage transfection with plasmid DNA.…”

Section: Stability Of the Nanovaccinementioning

confidence: 99%

Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses

Yin

Wang

Xiang

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

An attractive type of cancer immunotherapy is cancer therapeutic vaccines that induce antitumor immunity effectively. Although supportive results in the recent vaccine studies, there are still numerous drawbacks, such as poor stability, weak immunogenicity and strong toxicity, to be tackled for promoting the potency and durability of antitumor efficacy. NPs (Nanoparticles)-based vaccines offer unique opportunities to breakthrough the current bottleneck. As a rule, nanovaccines are new the generations of vaccines that use NPs as carriers and/or adjuvants. Several advantages of nanovaccines are constantly explored, including optimal nanometer size, high stability, plenty of antigen loading, enhanced immunogenicity, tunable antigen presentation, more retention in lymph nodes and promote patient compliance by a lower frequency of dosing. Here, we summarized the merits and highlight the diverse role nanovaccines play in improving antitumor responses.

show abstract

Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy

Cited by 17 publications

References 44 publications

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Engineering neoantigen vaccines to improve cancer personalized immunotherapy

Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses

Contact Info

Product

Resources

About